Authors: Seth J. Zost, Pavlo Gilchuk, Rita E. Chen, James Brett Case, Joseph X. Reidy, Andrew Trivette, Rachel S. Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, Elaine C. Chen, Elad Binshtein, Swathi Shrihari, Mario A. Ostrowski, Helen Y. Chu, Jonathan E. Didier, Keith W. MacRenaris, Taylor Jones, Samuel Day, Luke Myers, F. Eun-Hyung Lee, Doan C. Nguyen, Ignacio Sanz, David R. Martinez, Paul W. Rothlauf, Louis Marie Bloyet, Sean P. J. Whelan, Ralph S. Baric, Larissa B. Thackray, Michael S. Diamond, Robert H. Carnahan, James E. Crowe

Venue: N/A

Type: Publication

Abstract: Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes based on their reactivity to subdomains of S protein as well as ... (read more)

DOI: 10.1101/2020.05.12.091462 (Found 3 versions)